Bioglutide's 14% weight loss claim: what the data actually shows
Quick answer
Bioglutide is described as a quadruple agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors, with a reported 13.8% weight reduction in early-stage trial data and an oral tablet formulation currently under clinical investigation. As of mid-2025, no peer-reviewed Phase 2 or Phase 3 data for bioglutide has been published in a major medical journal, meaning all efficacy figures circulating online derive from preliminary or company-disclosed sources. Patients considering GLP-1 class therapies should be evaluated and managed by a licensed medical prescriber using drugs with established FDA approval status.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @drjonesdc actually say?
The core pitch here is that bioglutide is a next-generation GLP-1 drug that hits four receptors, including a novel IGF-1 pathway, and delivers "13.8% weight loss" in 13 weeks, all in a daily pill with no refrigeration required. Dr. Jones frames this as the natural evolution past semaglutide (one receptor), tirzepatide (two), and retatrutide (three), with bioglutide being the "big quad." He does, to his credit, acknowledge it is still in trials.
He also positions himself as a "weight loss expert" and coach who works with a provider, and closes with an audience engagement question about what weight loss future viewers want. The video is clearly promotional in framing even if it stops short of an explicit product pitch.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Bioglutide's 14% weight loss claim: what the data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Bioglutide's 14% weight loss claim: what the data actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Bioglutide is described as a quadruple agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors, with a reported 13.
FormBlends verdict
Bioglutide is described as a quadruple agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors, with a reported 13.8% weight reduction in early-stage trial data and an oral tablet formulation currently under clinical investigation. As of mid-2025, no peer-reviewed Phase 2 or Phase 3 data for bioglutide has been published in a major medical journal, meaning all efficacy figures circulating online derive from preliminary or company-disclosed sources. Patients considering GLP-1 class therapies should be evaluated and managed by a licensed medical prescriber using drugs with established FDA approval status.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Bioglutide is described as a quadruple agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors, with a reported 13.8% weight reduction in early-stage trial data and an oral tablet formulation currently under clinical investigation. As of mid-2025, no peer-reviewed Phase 2 or Phase 3 data for bioglutide has been published in a major medical journal, meaning all efficacy figures circulating online derive from preliminary or company-disclosed sources. Patients considering GLP-1 class therapies should be evaluated and managed by a licensed medical prescriber using drugs with established FDA approval status.
- Bioglutide has no peer-reviewed Phase 2 or Phase 3 trial data published in a major journal as of mid-2025. All efficacy numbers in circulation are preliminary.
- The multi-receptor agonist concept is real science. Retatrutide, a GLP-1/GIP/glucagon tri-agonist, showed up to 24.2% weight reduction at 48 weeks in Jastreboff et al. (2023, NEJM).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Bioglutide has no peer-reviewed Phase 2 or Phase 3 trial data published in a major journal as of mid-2025. All efficacy numbers in circulation are preliminary.
- The multi-receptor agonist concept is real science. Retatrutide, a GLP-1/GIP/glucagon tri-agonist, showed up to 24.2% weight reduction at 48 weeks in Jastreboff et al. (2023, NEJM).
- Oral GLP-1 delivery exists and is FDA-approved in the form of oral semaglutide (Rybelsus), so the pill format claim for bioglutide is plausible in principle, not confirmed for this specific compound.
- A Doctor of Chiropractic (DC) cannot legally prescribe GLP-1 medications in the U.S. Framing oneself as a GLP-1 expert without clarifying prescribing limitations is a credential misrepresentation risk.
- Comparing 13.8% weight loss at 13 weeks to approved drug benchmarks is misleading without matching trial length. Semaglutide's landmark STEP 1 trial ran 68 weeks (Wilding et al., 2021, NEJM).
- If someone is currently selling bioglutide as an available product, it is not an FDA-approved drug. It may be a research peptide or compounded substance with unverified purity and safety data.
- The four-receptor framework including IGF-1 for muscle preservation is speculative for this compound. IGF-1 biology is established; its application to bioglutide's clinical profile is not yet published evidence.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Lasting Weight Loss · TikTok creator
107.1K views on this video
Bioglutide: 14% ⬇️ in 13 weeks! (& NO weekly shots!) #fyp #glp1 #foryoupagе #glp1medication #glp1community
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Lasting Weight Loss, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.